Moderna 2026-2027 Spikevax and mNEXSPIKE COVID-19 vaccines OKd
U.S. FDA approves Moderna 2026-2027 Spikevax and mNEXSPIKE COVID-19 vaccines targeting JN.1-lineage XFG for high-risk and 65+ patients
- Moderna plans $2.0 billion private placement of convertible senior notes due 2032, with $300 million option.
- Company plans capped call transactions intended to limit potential dilution from conversions of the convertible notes.
- Net proceeds expected to fund general corporate purposes, including oncology growth initiatives and debt repayment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.